Skip to main content

Day: October 26, 2019

Merus annonce une présentation et une affiche sur les programmes MCLA-128 et MCLA-129 lors du Congrès international sur les cibles moléculaires et les thérapeutiques anticancéreuses de l’AACR-NCI-EORTC

UTRECHT, Pays-Bas et BOSTON, 26 oct. 2019 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq : MRUS) (« Merus », « nous », « notre » ou la « Société »), société spécialisée en immuno-oncologie de stade clinique qui développe Biclonics®, un traitement innovant à base d’anticorps bispécifiques humains pleine longueur, a annoncé aujourd’hui que les données de ses programmes MCLA-128 et MCLA-129 seront présentées lors du Congrès international sur les cibles moléculaires et les thérapeutiques anticancéreuses de l’AACR-NCI-EORTC qui se tiendra du 26 au 30 octobre 2019 à Boston, dans le Massachusetts. Renseignements sur la présentation et l’affiche : MCLA-128Titre de la présentation : Clinical proof-of-concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers (Preuve de concept clinique pour MCLA-128,...

Continue reading

Merus kündigt Präsentation und Poster über MCLA-128 und MCLA-129 Programme auf der AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics an

UTRECHT, Niederlande und BOSTON, USA, Oct. 26, 2019 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) („Merus‟, „wir‟, „unser‟ oder das „Unternehmen‟), ein Unternehmen für bispezifische Antikörper im klinischen Stadium, das Biclonics®, innovative, vollständige menschliche bispezifische Antikörpertherapeutika entwickelt, gab heute bekannt, dass Daten aus seinen Programmen MCLA-128 und MCLA-129 auf der AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics präsentiert werden, die vom 26. bis 30. Oktober 2019 in Boston, USA, stattfindet. Präsentations- und Posterdetails: MCLA-128PräsentationTitel: Clinical proof-of-concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancersAutoren:  Alison M Schram, Eileen M O’Reilly, Romel Somwar, Ryma Benayed, Sara Shameem, Thrusha Chauhan,...

Continue reading

AHMSA Announces Third Quarter 2019 Results

MONCLOVA, Coahuila, Oct. 26, 2019 (GLOBE NEWSWIRE) — Altos Hornos de México, S.A.B. de C.V. and Subsidiaries (“AHMSA” or “the Company”) (BMV: AHMSA) reported financial results for the Third Quarter period ended September 30, 2019 (3Q 2019). Financial and operating figures included in this report are unaudited and are based on AHMSA’s operating figures and financial statements; they are prepared in accordance with International Financial Reporting Standards (IFRS) and are expressed in U.S. dollars (US$) and metric tons (MT), unless otherwise indicated.3Q 2019 HighlightsAdjusted EBITDA was US$ (40.4) million, a 149.6% decline compared to (US$ 81.5 million) in 3Q 2018.  Adjusted EBITDA for the Steel Segment was US$ (31.0) million, a 132.1% decline compared to US$ 96.6 million in 3Q 2018. This result was explained by the following:Steel...

Continue reading

Core Gold Provides Update on Amendment of Promissory Notes and Convertible Debt

VANCOUVER, British Columbia, Oct. 25, 2019 (GLOBE NEWSWIRE) — Core Gold Inc. (“Core Gold” or the “Company“) (TSX-V: CGLD, OTCQX: CGLDF) is today providing an update regarding the proposed amendments announced by Core Gold on August 21, 2019 to promissory notes issued by Core Gold in the aggregate principal amount of US$1.5 million (the “Promissory Notes“) and (ii) convertible promissory notes issued by Core Gold in the aggregate principal amount of US$1 million (the “Convertible Notes“, and together with the Promissory Notes, the “Core Debt“).As announced by Core Gold on August 21, 2019, Core Gold entered into debt extension and amending agreements (the “Agreements“) with each of Vertex Managed Value Portfolio and Vertex Enhanced Income Fund (collectively, “Vertex“)...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.